President Biden has left out of his American Families human-capital investment plan drug pricing reforms that Democratic leaders in Congress have pressed him hard to add. House Speaker Nancy Pelosi (D-Calif.), House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.),
…
A federal judge in Delaware yesterday declined to add hospital groups as third parties to a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. But he left the door open to letting the groups participate as
…
President Biden might exclude legislation to reduce what consumers and the federal government pay for prescription drugs from his American Families human and capital investment initiative, news organizations report this morning. Biden is scheduled to describe his infrastructure investment plan
…
A federal district judge in Wilmington, Del., ruled this morning that six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements.
In a ruling delivered from the bench,
…
UPDATE Thursday, April 22, 2021, 1:00 p.m. EDT—U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress
…
U.S. Justice Department (DOJ) lawyers asked federal district courts in Indiana and New Jersey this week to condemn, not condone, drugmakers Eli Lilly and Sanofi’s “extra-statutory self-help efforts to rewrite” the 340B statute “under the guise of ‘program integrity’” and
…
Six hospital groups asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Tuesday to state “immediately and definitively” that six drug manufacturers’ refusals to offer 340B discounts on drugs dispensed by contract pharmacies are illegal.
They also asked
…
UPDATED Monday, April 26, 2021, 9:00 a.m. EDT—President Biden signed the two bills into law on April 23.
The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for
…
The U.S. Health and Human Services Department (HHS) can “move forward with implementing” the stalled 340B administrative dispute resolution (ADR) process, and it is “actively considering additional options for agency enforcement of the 340B statute” against drug manufacturers denying 340B
…*Sign up for news summaries and alerts from 340B Report